370 related articles for article (PubMed ID: 28111985)
1. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
[TBL] [Abstract][Full Text] [Related]
2. Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.
Qian J; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y
Cardiovasc Drugs Ther; 2016 Apr; 30(2):129-41. PubMed ID: 26861490
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
[TBL] [Abstract][Full Text] [Related]
4. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
[TBL] [Abstract][Full Text] [Related]
5. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
[TBL] [Abstract][Full Text] [Related]
6. PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation.
Ren Y; Sun C; Sun Y; Tan H; Wu Y; Cui B; Wu Z
Vascul Pharmacol; 2009; 51(2-3):169-74. PubMed ID: 19540934
[TBL] [Abstract][Full Text] [Related]
7. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
Bénardeau A; Verry P; Atzpodien EA; Funk JM; Meyer M; Mizrahi J; Winter M; Wright MB; Uhles S; Sebokova E
Diabetes Obes Metab; 2013 Feb; 15(2):164-74. PubMed ID: 22958363
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins.
Wu JS; Lin TN; Wu KK
J Cell Physiol; 2009 Jul; 220(1):58-71. PubMed ID: 19229877
[TBL] [Abstract][Full Text] [Related]
9. Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor alpha but not gamma activators.
Yeh CH; Chen TP; Lee CH; Wu YC; Lin YM; Lin PJ
Shock; 2006 Sep; 26(3):262-70. PubMed ID: 16912651
[TBL] [Abstract][Full Text] [Related]
10. The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.
Werner CM; Schirmer SH; Gensch C; Pavlickova V; Pöss J; Wright MB; Böhm M; Laufs U
Br J Pharmacol; 2014 May; 171(10):2685-703. PubMed ID: 24467636
[TBL] [Abstract][Full Text] [Related]
11. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
[TBL] [Abstract][Full Text] [Related]
12. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
Boujon V; Uhlemann R; Wegner S; Wright MB; Laufs U; Endres M; Kronenberg G; Gertz K
J Mol Med (Berl); 2019 Aug; 97(8):1127-1138. PubMed ID: 31147725
[TBL] [Abstract][Full Text] [Related]
13. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
Deehan R; Maerz-Weiss P; Catlett NL; Steiner G; Wong B; Wright MB; Blander G; Elliston KO; Ladd W; Bobadilla M; Mizrahi J; Haefliger C; Edgar A
PLoS One; 2012; 7(4):e35012. PubMed ID: 22514701
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
15. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
[TBL] [Abstract][Full Text] [Related]
16. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Erdmann E; Califf R; Gerstein HC; Malmberg K; Ruilope L; Schwartz GG; Wedel H; Volz D; Ditmarsch M; Svensson A; Bengus M
Am Heart J; 2015 Jul; 170(1):117-22. PubMed ID: 26093872
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
Han CL; Qu CZ
J Cardiovasc Pharmacol; 2020 Apr; 75(4):351-357. PubMed ID: 31929323
[TBL] [Abstract][Full Text] [Related]
18. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
Sturm S; Seiberling M; Weick I; Paehler A; Funk C; Ruf T
Clin Ther; 2012 Feb; 34(2):420-9. PubMed ID: 22244809
[TBL] [Abstract][Full Text] [Related]
19. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Dietz M; Mohr P; Kuhn B; Maerki HP; Hartman P; Ruf A; Benz J; Grether U; Wright MB
ChemMedChem; 2012 Jun; 7(6):1101-11. PubMed ID: 22489042
[TBL] [Abstract][Full Text] [Related]
20. Curcumin protects neurons against oxygen-glucose deprivation/reoxygenation-induced injury through activation of peroxisome proliferator-activated receptor-γ function.
Liu ZJ; Liu HQ; Xiao C; Fan HZ; Huang Q; Liu YH; Wang Y
J Neurosci Res; 2014 Nov; 92(11):1549-59. PubMed ID: 24975470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]